

Source: Okayama University (JAPAN), Public Relations Division

For immediate release: 3 August 2021

Okayama University research: Repurposing cancer drugs: An innovative therapeutic strategy to fight bone cancer.

(Okayama, 3 August) **In a study reported in the journal *Molecular Cancer Therapeutics*, researchers from Okayama University describe the effects of pexidartinib, a drug targeting macrophages infiltrating into a tumor, for bone and soft-tissue malignancies.**

Sarcoma is a rare form of cancer that often originates within bones and then spreads to other organs. A distinct feature of cancer and sarcoma is the presence of tumor-associated macrophages (TAMs). These are usually healthy blood cells which have been converted by cancer cells to turn against the body and help their perpetrators spread. Now, in a collaboration between Okayama University and the Memorial Sloan Kettering Cancer Center, a research team has shown that PLX3397 (pexidartinib), a drug that can inhibit the formation of TAMs, is effective in mitigating the spread of sarcoma.

Colony stimulating factor 1 (CSF-1) is a cytokine secreted by cancer cells which oversees the creation of TAMs. PLX3397 is known to effectively inhibit CSF-1/CSF-1 receptor (CSF-1R) on TAMs. Now, in this study the researchers investigated whether this ability of PLX3397 could be leveraged in sarcoma too.

Sarcoma cells were first analyzed to confirm that they secreted CSF-1. Next, blood cells were extracted from mice and grown in the same environment as these sarcoma cells. Subsequently, the blood cells started proliferating faster and showing TAM-like tendencies. When the genetic makeup of these nascent TAMs was assessed, the team found showed that they had transformed into M2-like macrophages, a subtype that indeed promotes tumor growth. The mixture of cells was then treated with varying doses of PLX3397 to find that the drug curbed the transformation, growth, and movement of TAMs.

Next, the effects of PLX3397 in a mouse model of bone cancer were examined. Sarcoma cells were transplanted into the tibial bones of mice and monitored for a few weeks. By the end of 3 weeks, the cancer had grown and spread into the lungs of these mice. However, mice who had been treated with high doses of PLX3397 not only showed smaller tumors within their bones, but also displayed no signs of cancer within their lungs. Lastly, the team extracted tumor tissues from these mice to study the cancer cells closely. It was found that PLX3397 also increased the presence of cancer-fighting immune cells, CD8 T cells, within these tumors. PLX3397 thus showed an effective inhibition of sarcoma in cellular and animal models.

“Our preclinical results show that PLX3397 has strong macrophage- and T cell-modulating effects that may translate into cancer immunotherapy for bone and soft tissue sarcomas,”


conclude the researchers. Although successful results still need to be shown in human clinical trials, this study paves the way for an effective new way to tackle sarcoma.


### Background

**Sarcoma:** Sarcoma is a form of cancer that originates within bone tissue or soft tissues such as the muscles, fat, or tendons. The former type, osteosarcoma, is the most common subtype of bone cancer and affects mostly teens and young adults. Sarcomas have a high potential of spread to distant organs, predominantly to the lungs.

At present, nearly a third of patients respond very poorly to the available therapies for sarcoma. Thus, development of targeted therapies and/or immunotherapies for bone and soft-tissue sarcomas is crucial.

**Tumor-associated macrophages (TAMs):** In certain forms of cancer, innocuous blood cells are recruited by cancerous ones and converted into specialized immune cells called TAMs. Under usual circumstances, macrophages help the body ward off invaders and combat infection (M1-like macrophages). However, the CSF-1 secreted by cancer cells within the tumor milieu generates macrophages which promote the growth and progression of tumors (M2-like macrophages). Owing to this property, inhibition of CSF-1/CSF-1R is being investigated as a therapeutic target against TAMs in the different cancerous tissues.





### Caption

**A.** The growth of TAMs was curbed with increasing doses of PLX3397 treatment.

**B.** The growth of tumors at the site of transplantation (circled) was greatly contained with high doses of PLX3397 compared to the control (PBS).

### Reference

Tomohiro Fujiwara, Mohamed A. Yakoub, Andrew Chandler, Alexander B. Christ, Guangli Yang, Ouathék Ouerfelli, Vinagolu K. Rajasekhar, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Yildirim Dogan, Malcom A.S. Moore, Toshiyoshi Fujiwara, Toshifumi Ozaki, Ed Purdue, John H. Healey. CSF-1/CSF-1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-Cell Infiltration in the Sarcoma Microenvironment. *Molecular Cancer Therapeutics*, 2021 Jun 4;molcanther.0591.2020.

DOI: 10.1158/1535-7163.MCT-20-0591

<https://mct.aacrjournals.org/content/early/2021/06/04/1535-7163.MCT-20-0591>

### Correspondence to

Assistant Professor FUJIWARA Tomohiro, M.D.,Ph.D.  
Department of Orthopaedic Surgery,  
Graduate School of Medicine, Dentistry and Pharmaceutical Science,  
Okayama University, 2-5-1 Shikata-cho, Kita-ku,  
Okayama 700-8558, Japan  
E-mail: tomomedvn@okayama-u.ac.jp



Assistant Professor  
FUJIWARA Tomohiro

### Further information

Okayama University

1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan

Public Relations Division

E-mail: [www-adm@adm.okayama-u.ac.jp](mailto:www-adm@adm.okayama-u.ac.jp)

Website: [http://www.okayama-u.ac.jp/index\\_e.html](http://www.okayama-u.ac.jp/index_e.html)

Okayama Univ. e-Bulletin: <http://www.okayama-u.ac.jp/user/kouhou/ebulletin/>

We love OKAYAMA UNIVERSITY:

<https://www.youtube.com/watch?v=7cXlIttQIk3E>

Okayama University Image Movie (2020):

<https://www.youtube.com/watch?v=vQxeL0ztSLA>

Okayama University supports the Sustainable Development Goals: <https://sdgs.okayama-u.ac.jp/en/>



### Okayama University Medical Research Updates (OU-MRU)

The whole volume : [OU-MRU \(1-\)](#)

Vol.1 : [Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing](#)

Vol.2 : [Ensuring a cool recovery from cardiac arrest](#)

Vol.3 : [Organ regeneration research leaps forward](#)

Vol.4 : [Cardiac mechanosensitive integrator](#)

Vol.5 : [Cell injections get to the heart of congenital defects](#)

Vol.6 : [Fourth key molecule identified in bone development](#)

Vol.7 : [Anticancer virus solution provides an alternative to surgery](#)

Vol.8 : [Light-responsive dye stimulates sight in genetically blind patients](#)

Vol.9 : [Diabetes drug helps towards immunity against cancer](#)

Vol.10 : [Enzyme-inhibitors treat drug-resistant epilepsy](#)

Vol.11 : [Compound-protein combination shows promise for arthritis treatment](#)

Vol.12 : [Molecular features of the circadian clock system in fruit flies](#)

Vol.13 : [Peptide directs artificial tissue growth](#)

Vol.14 : [Simplified boron compound may treat brain tumours](#)

Vol.15 : [Metamaterial absorbers for infrared inspection technologies](#)

Vol.16 : [Epigenetics research traces how crickets restore lost limbs](#)

Vol.17 : [Cell research shows pathway for suppressing hepatitis B virus](#)

Vol.18 : [Therapeutic protein targets liver disease](#)

Vol.19 : [Study links signalling protein to osteoarthritis](#)

Vol.20 : [Lack of enzyme promotes fatty liver disease in thin patients](#)

Vol.21 : [Combined gene transduction and light therapy targets gastric cancer](#)

Vol.22 : [Medical supportive device for hemodialysis catheter puncture](#)

Vol.23 : [Development of low cost oral inactivated vaccines for dysentery](#)

Vol.24 : [Sticky molecules to tackle obesity and diabetes](#)

Vol.25 : [Self-administered aroma foot massage may reduce symptoms of anxiety](#)

- Vol.26 : [Protein for preventing heart failure](#)
- Vol.27 : [Keeping cells in shape to fight sepsis](#)
- Vol.28 : [Viral-based therapy for bone cancer](#)
- Vol.29 : [Photoreactive compound allows protein synthesis control with light](#)
- Vol.30 : [Cancer stem cells' role in tumor growth revealed](#)
- Vol.31 : [Prevention of RNA virus replication](#)
- Vol.32 : [Enzyme target for slowing bladder cancer invasion](#)
- Vol.33 : [Attacking tumors from the inside](#)
- Vol.34 : [Novel mouse model for studying pancreatic cancer](#)
- Vol.35 : [Potential cause of Lafora disease revealed](#)
- Vol.36 : [Overloading of protein localization triggers cellular defects](#)
- Vol.37 : [Protein dosage compensation mechanism unravelled](#)
- Vol.38 : [Bioengineered tooth restoration in a large mammal](#)
- Vol.39 : [Successful test of retinal prosthesis implanted in rats](#)
- Vol.40 : [Antibodies prolong seizure latency in epileptic mice](#)
- Vol.41 : [Inorganic biomaterials for soft-tissue adhesion](#)
- Vol.42 : [Potential drug for treating chronic pain with few side effects](#)
- Vol.43 : [Potential origin of cancer-associated cells revealed](#)
- Vol.44 : [Protection from plant extracts](#)
- Vol.45 : [Link between biological-clock disturbance and brain dysfunction uncovered](#)
- Vol.46 : [New method for suppressing lung cancer oncogene](#)
- Vol.47 : [Candidate genes for eye misalignment identified](#)
- Vol.48 : [Nanotechnology-based approach to cancer virotherapy](#)
- Vol.49 : [Cell membrane as material for bone formation](#)
- Vol.50 : [Iron removal as a potential cancer therapy](#)
- Vol.51 : [Potential of 3D nanoenvironments for experimental cancer](#)
- Vol.52 : [A protein found on the surface of cells plays an integral role in tumor growth and sustenance](#)
- Vol.53 : [Successful implantation and testing of retinal prosthesis in monkey eyes with retinal degeneration](#)
- Vol.54 : [Measuring ion concentration in solutions for clinical and environmental research](#)
- Vol.55 : [Diabetic kidney disease: new biomarkers improve the prediction of the renal prognosis](#)
- Vol.56 : [New device for assisting accurate hemodialysis catheter placement](#)
- Vol.57 : [Possible link between excess chewing muscle activity and dental disease](#)
- Vol.58 : [Insights into mechanisms governing the resistance to the anti-cancer medication cetuximab](#)
- Vol.59 : [Role of commensal flora in periodontal immune response investigated](#)
- Vol.60 : [Role of commensal microbiota in bone remodeling](#)
- Vol.61 : [Mechanical stress affects normal bone development](#)
- Vol.62 : [3D tissue model offers insights into treating pancreatic cancer](#)
- Vol.63 : [Promising biomarker for vascular disease relapse revealed](#)
- Vol.64 : [Inflammation in the brain enhances the side-effects of hypnotic medication](#)
- Vol.65 : [Game changer: How do bacteria play Tag?](#)

- Vol.66 : [Is too much protein a bad thing?](#)
- Vol.67 : [Technology to rapidly detect cancer markers for cancer diagnosis](#)
- Vol.68 : [Improving the diagnosis of pancreatic cancer](#)
- Vol.69 : [Early gastric cancer endoscopic diagnosis system using artificial intelligence](#)
- Vol.70 : [Prosthetics for Retinal Stimulation](#)
- Vol.71 : [The nervous system can contribute to breast cancer progression](#)
- Vol.72 : [Synthetic compound provides fast screening for potential drugs](#)
- Vol.73 : [Primary intraocular lymphoma does not always spread to the central nervous system](#)
- Vol.74 : [Rising from the ashes—dead brain cells can be regenerated after traumatic injury](#)
- Vol.75 : [More than just daily supplements — herbal medicines can treat stomach disorders](#)
- Vol.76 : [The molecular pathogenesis of muscular dystrophy-associated cardiomyopathy](#)
- Vol.77 : [Green leafy vegetables contain a compound which can fight cancer cells](#)
- Vol.78 : [Disrupting blood supply to tumors as a new strategy to treat oral cancer](#)
- Vol.79 : [Novel blood-based markers to detect Alzheimer’s disease](#)
- Vol.80 : [A novel 3D cell culture model sheds light on the mechanisms driving fibrosis in pancreatic cancer](#)
- Vol.81 : [Innovative method for determining carcinogenicity of chemicals using iPS cells](#)
- Vol.82 : [Making memories — the workings of a neuron revealed](#)
- Vol.83 : [Skipping a beat — a novel method to study heart attacks](#)
- Vol.84 : [Friend to Foe—When Harmless Bacteria Turn Toxic](#)
- Vol.85 : [Promising imaging method for the early detection of dental caries](#)
- Vol.86 : [Plates and belts — a toolkit to prevent accidental falls during invasive vascular procedures](#)
- Vol.87 : [Therapeutic potential of stem cells for treating neurodegenerative disease](#)
- Vol.88 : [Nanotechnology for making cancer drugs more accessible to the brain](#)
- Vol.89 : [Studying Parkinson’s disease with face-recognition software](#)
- Vol.90 : [High levels of television exposure affect visual acuity in children](#)
- Vol.91 : [Meeting high demand: Increasing the efficiency of antiviral drug production in bacteria](#)
- Vol.92 : [Numerical modelling to assist the development of a retinal prosthesis](#)



Okayama University supports the Sustainable Development Goals



◆About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

Website: [http://www.okayama-u.ac.jp/index\\_e.html](http://www.okayama-u.ac.jp/index_e.html)



Japan (日本)



Hirofumi Makino, M.D., Ph.D.  
President, Okayama University



“Okayama University supports the Sustainable Development Goals”



**Okayama University Integrated Report**

=> [click](#)



An integrated report is intended to explain how an organization creates value over time through an organic integration of the vision and the combination of financial information and other information. Through this report we hope to promote greater interest in Okayama University among readers everywhere. In order to help us make improvements in future editions, we encourage you to contact us with any comments and suggestions you may have.